Relaxivity Contrast Imaging as Biomarker of Muscle Degeneration in ALS
弛豫对比成像作为 ALS 肌肉退化的生物标志物
基本信息
- 批准号:10783525
- 负责人:
- 金额:$ 68.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:ALS patientsAgeAmyotrophic Lateral SclerosisAntisense Oligonucleotide TherapyArchitectureAtypiaBiologicalBiological MarkersCessation of lifeCharacteristicsClinicalClinical MarkersClinical TrialsData AnalysesDiameterDiseaseDisease MarkerDisease ProgressionEdemaExhibitsFatty acid glycerol estersFiberFoundationsFunctional ImagingFunctional disorderGoalsHealthHospitalsHumanImageMagnetic Resonance ImagingMeasuresMethodsMotor CortexMotor NeuronsMuscleMuscular AtrophyNerve DegenerationNeurologicNeuromuscular DiseasesPathologicPatient CarePatient-Centered CarePatientsPerformancePharmacodynamicsPhase II/III Clinical TrialProcessProtocols documentationQuality ControlReadinessReproducibilityResearchRespiratory physiologyRodent ModelSample SizeSpinalTherapeutic InterventionUpper ExtremityValidationVertebral columnbiomarker discoverybiophysical propertiesclinical heterogeneitycomputer frameworkcontrast imagingcost effectivedata acquisitiondensitydesigndrug developmentdrug discoveryearly detection biomarkersimaging approachimaging biomarkerimprovedinnovationmultidisciplinarymuscle degenerationmuscle strengthnervous system disorderneuroimagingnext generationnon-invasive imagingnovelpre-clinicalrate of changeresearch clinical testingresponseresponse biomarkersexstructural imagingsuperoxide dismutase 1treatment effecttreatment response
项目摘要
ABSTRACT
Amyotrophic Lateral Sclerosis (ALS) is characterized by loss of spinal and cortical motor neurons,
resulting in progressive muscle atrophy and eventually, death. The clinical heterogeneity and rapid
progression of ALS continues to confound the identification of treatment response biomarkers.
Currently, clinical trials (and practice) are forced to rely upon downstream indicators of disease status
such as muscle strength, respiratory function and functional rating scales. Such measures, although
validated, have a number of limitations. First, they have significant inter-rater variability. Second, the
measures usually have relatively slow rates of change and thus, require months and even years to
detect a treatment effect. These challenges underscore the unmet need for sensitive, reproducible, and
non-invasive biomarkers of therapy response. To overcome these limitations, we propose to develop a
non-invasive imaging approach, termed relaxivity contrast imaging (RCI). Unlike existing image-based
biomarkers that reflect downstream changes in pathophysiology (e.g. T2 - edema, fat fraction), RCI is
uniquely sensitive to myofiber architectural features (e.g. reduced fiber diameter and density, fiber
atypia) exhibited by ALS patients. We hypothesize that RCI could serve as a
pharmacodynamic/response biomarker to show efficacy of and biological response to therapeutic
interventions in Phase 2/3 clinical trials of agents designed to slow or reverse neurodegeneration in
ALS patients. To develop RCI, we will use a validated computational framework to systematically
characterize the biophysical basis of RCI in the context of muscle degeneration and treatment response
and use it to identify optimal acquisition and analysis strategies for applying RCI in a clinical trial. In
preclinical rodent models of ALS, we will verify the association between RCI-based biomarkers and
pathologic markers of muscle architecture and establish the utility of RCI-based biomarkers to detect
response to therapy. In humans, we will characterize performance characteristics and repeatability of
RCI protocols in healthy controls and ALS patients. To further refine RCI, we will establish quality
control measures for RCI data acquisition and analysis and characterize age- and sex- dependent
reference intervals of RCI-based biomarkers in healthy controls. Finally, we will establish the sensitivity
of RCI-based biomarkers to disease progression in ALS patients and compare to other advanced
image-based biomarkers and routine clinical markers of disease status. Ultimately, RCI has the
potential to serve as a quantitative, myofiber-specific, image-based biomarker of early therapeutic
response for ALS, potentially enabling smaller sample sizes, earlier Go/No Go decisions, more cost-
effective clinical trials and, ultimately, improved patient care.
摘要
肌萎缩性侧索硬化症(ALS)的特征在于脊髓和皮质运动神经元的丧失,
导致肌肉萎缩最终死亡临床异质性和快速
ALS的进展继续混淆治疗反应生物标志物的鉴定。
目前,临床试验(和实践)被迫依赖于疾病状态的下游指标
例如肌肉力量、呼吸功能和功能评定量表。这些措施虽然
经过验证,有一些限制。首先,他们有显著的评分者间差异。二是
衡量标准的变化速度通常相对较慢,因此需要数月甚至数年的时间来
检测治疗效果。这些挑战强调了对敏感的、可再现的、
治疗反应的非侵入性生物标志物。为了克服这些限制,我们建议制定一个
非侵入性成像方法,称为弛豫对比成像(RCI)。与现有的基于图像的
反映病理生理学下游变化的生物标志物(例如T2 -水肿、脂肪分数),RCI是
对肌纤维结构特征(例如,减小的纤维直径和密度,纤维
ALS患者的症状。我们假设RCI可以作为
药效学/反应生物标志物,以显示治疗的疗效和生物学反应
在旨在减缓或逆转神经退行性变的药物的2/3期临床试验中,
ALS患者为了开发RCI,我们将使用经过验证的计算框架,
在肌肉变性和治疗反应的背景下表征RCI的生物物理基础
并使用它来确定在临床试验中应用RCI的最佳采集和分析策略。在
ALS的临床前啮齿动物模型,我们将验证基于RCI的生物标志物和
肌肉结构的病理标志物,并建立基于RCI的生物标志物的实用性,以检测
对治疗的反应。在人类中,我们将描述性能特征和重复性,
健康对照和ALS患者的RCI方案。为了进一步完善RCI,我们将建立质量
RCI数据采集和分析的控制措施,并描述年龄和性别依赖性
健康对照中基于RCI的生物标志物的参考区间。最后,我们将建立灵敏度
基于RCI的生物标志物对ALS患者疾病进展的影响,并与其他晚期
基于图像的生物标志物和疾病状态的常规临床标志物。最终,RCI拥有
作为一种定量的、肌纤维特异性的、基于图像的生物标志物,
ALS的响应,可能实现更小的样本量,更早的Go/No Go决策,更多的成本-
有效的临床试验,并最终改善患者护理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher Chad Quarles其他文献
Christopher Chad Quarles的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher Chad Quarles', 18)}}的其他基金
Imaging-based tumor forecasting to predict brain tumor progression and response to therapy
基于成像的肿瘤预测可预测脑肿瘤进展和治疗反应
- 批准号:
10706461 - 财政年份:2022
- 资助金额:
$ 68.65万 - 项目类别:
Imaging-based tumor forecasting to predict brain tumor progression and response to therapy
基于成像的肿瘤预测可预测脑肿瘤进展和治疗反应
- 批准号:
10367617 - 财政年份:2022
- 资助金额:
$ 68.65万 - 项目类别:
Relaxivity Contrast Imaging as Biomarker of Muscle Degeneration in ALS
弛豫对比成像作为 ALS 肌肉退化的生物标志物
- 批准号:
10357431 - 财政年份:2021
- 资助金额:
$ 68.65万 - 项目类别:
Multi-parametric Perfusion MRI for Therapy Response Assessment in Brain Cancer
多参数灌注 MRI 用于脑癌治疗反应评估
- 批准号:
9927886 - 财政年份:2020
- 资助金额:
$ 68.65万 - 项目类别:
Establishing the validity of brain tumor perfusion imaging
建立脑肿瘤灌注成像的有效性
- 批准号:
9754786 - 财政年份:2017
- 资助金额:
$ 68.65万 - 项目类别:
Establishing the Validity of Brain Tumor Perfusion Imaging
建立脑肿瘤灌注成像的有效性
- 批准号:
10734997 - 财政年份:2017
- 资助金额:
$ 68.65万 - 项目类别:
Establishing the validity of brain tumor perfusion imaging
建立脑肿瘤灌注成像的有效性
- 批准号:
10373105 - 财政年份:2017
- 资助金额:
$ 68.65万 - 项目类别:
MRI Assessment of Tumor Perfusion, Permeability and Cellularity
肿瘤灌注、渗透性和细胞结构的 MRI 评估
- 批准号:
9182174 - 财政年份:2011
- 资助金额:
$ 68.65万 - 项目类别:
MRI Assessment of Tumor Perfusion, Permeability and Cellularity
肿瘤灌注、渗透性和细胞结构的 MRI 评估
- 批准号:
8703037 - 财政年份:2011
- 资助金额:
$ 68.65万 - 项目类别:
MRI Assessment of Tumor Perfusion, Permeability and Cellularity
肿瘤灌注、渗透性和细胞结构的 MRI 评估
- 批准号:
10062866 - 财政年份:2011
- 资助金额:
$ 68.65万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 68.65万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 68.65万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 68.65万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 68.65万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 68.65万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 68.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 68.65万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 68.65万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 68.65万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 68.65万 - 项目类别:
Research Grant